Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey
Columbia University
Winship Cancer Institute of Emory University
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center Identifier:
First received: February 23, 2006
Last updated: September 25, 2015
Last verified: September 2015